Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim
29.6.2021 09:30:00 EEST | Business Wire | Press release
Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.
This preferred partnership allows Boehringer Ingelheim, a leading research driven pharmaceutical company, to incorporate several design elements, synthesize, profile, and then characterize a wide range of chemotypes against key targets of interest in swift optimization cycles. The partnership also allows for the integrated up-scaling of compounds for larger pre-clinical studies. Biology screening of appropriate chemical moieties to drive decision making with speed and accuracy is also included in the partnership. Aragen will dedicate a sizeable portion of its campus in Hyderabad to support this alliance.
"We at Aragen believe that ‘In Every Molecule is the Possibility for Better Health’, and are excited about the opportunity to expand our partnership with Boehringer Ingelheim, a global leader in the discovery and development of novel medicines. It has been our privilege to collaborate with the scientists at Boehringer Ingelheim, and we thank them for their trust and confidence in the Aragen team. Together, we look forward to advancing Boehringer Ingelheim’s innovative approaches into successful clinical outcomes that can have the potential to ultimately benefit patients,” said Manni Kantipudi, CEO at Aragen.
About Aragen
Aragen Life Sciences Pvt Ltd (“Aragen”) is a global leader in providing discovery, development and manufacturing solutions for life sciences firms. With a team of over 3100 professionals, and through a network of sites around the world, we offer a seamless, integrated platform to advance customer programs from discovery through commercialization for both small molecules and biologics. Established in 2001, Aragen now serves over 450 customers worldwide across multiple modalities and therapeutic areas. For more information, visit www.aragen.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005162/en/
Contact information
Aragen Life Sciences: Sarat Patanaik, +91 95732 80064, sarat.patanaik@aragen.com
MediaMedic Communications Pvt.Ltd.: Bhavna Pathak, +918830654608, info@mediamedichealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TradingHub Secures Strategic Investment From Nordic Capital to Accelerate Next Phase of Growth16.3.2026 18:00:00 EET | Press release
TradingHub, a leading provider of trade surveillance technology for global financial institutions, has agreed to partner with Nordic Capital which will become the company’s majority shareholder. The investment marks a significant milestone in TradingHub’s journey and provides strong backing to support the company’s continued growth and innovation. Existing investor Summit Partners and TradingHub’s co-founder Neil Walker will continue to hold minority positions in the company following the close of the transaction. With the support of Nordic Capital, TradingHub will accelerate its expansion across global markets while continuing to invest in the development of its trade surveillance platform. The company plans to further strengthen its capabilities across asset classes, including equities, and continue its expansion into new markets and geographies. Founded in 2010 and today operating from offices in London, Toronto, Singapore and Sydney, TradingHub has built a highly differentiated tec
Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation16.3.2026 17:10:00 EET | Press release
The third edition of the Umrah and Ziyarah Forum will commence in Madinah on Monday, March 30, 2026. The forum is organized by the Ministry of Hajj and Umrah, in partnership with the Pilgrim Experience Program, at the King Salman International Convention Center, with wide participation from business leaders, decision-makers, and specialists in the Umrah and Ziyarah services ecosystem from around the world to exchange expertise and explore ways to further enrich the experience of the Guests of Allah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316471639/en/ Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation (Photo: AETOSWire) This year’s edition builds on the success of the forum's previous editions, reaffirming its position as a global platform for advancing the Umrah and Ziyarah services ecosystem. It focuses on enhancing services for Umrah performers and visitors, in line with the gro
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 15:00:00 EET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Resident Evil Requiem in 2026, and orchestral concerts in Japan,
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 15:00:00 EET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the company will continue to offer a grand prize of $1 million for Capcom Cup and will increase the total prize pool for Street Fighter League from $200,000
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 15:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (energization) tests in 2027. It also highlights Helical Fusion’s role in leading a “Japan-style public–private partnership (PPP)” for fus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom